Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 29;18(2):285–292. doi: 10.5114/aoms/143476

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2021 Termedia & Banach

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

PMC Copyright notice

Proportion of patients achieving LDL-C goals at Week 12 on alirocumab treatment. A – According to adherence to alirocumab. B – Both overall and according to background statin intensity*. C – According to prior ezetimibe medication (mITT population)

*High-intensity statin was defined as atorvastatin 40 or 80 mg, rosuvastatin 20 or 40 mg, or simvastatin 80 mg daily; low/moderate-intensity statin was defined as all other statins and/or doses. LDL-C – low-density lipoprotein cholesterol, mITT – modified intention-totreat.